Wells Fargo analyst Yanan Zhu assigned a Buy rating to Autolus Therapeutics (AUTL – Research Report) yesterday and set a price target of $8.00. The company’s shares closed yesterday at $5.75.
Zhu covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Crispr Therapeutics AG, and Autolus Therapeutics. According to TipRanks, Zhu has an average return of 3.8% and a 42.57% success rate on recommended stocks.
Currently, the analyst consensus on Autolus Therapeutics is a Strong Buy with an average price target of $8.97, which is a 56.00% upside from current levels. In a report released yesterday, Needham also reiterated a Buy rating on the stock with a $8.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $7.45 and a one-year low of $1.61. Currently, Autolus Therapeutics has an average volume of 1.18M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Autolus Therapeutics (AUTL) Company Description:
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm’s portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.
Read More on AUTL:
- Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
- Autolus Therapeutics appoints Azelby to board of directors
- Autolus Therapeutics Announces Changes to its Board of Directors
- Autolus Therapeutics appoints Leiderman to board, Dhingra to step down
- Autolus Therapeutics presents clinical data updates at ASH Annual Meeting 2023
